Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
2014 · Blood · 623 citations
https://doi.org/10.1182/blood-2013-11-531327
P
Peter Wood
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
48
Papers
1.7K
Citations
16
h-index
20
i10-index
Peter Wood is an academic researcher from Case Western Reserve University. The author has contributed to research in topics: Lymphoma Diagnosis and Treatment & Chronic Lymphocytic Leukemia Research & Venous Thromboembolism Diagnosis and Management. The author has an h-index of 16, co-authored 41 publications.
ORCID: 0000-0002-4226-6507Papers by this author
worksFirst-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study
2019 · Journal of Clinical Oncology · 286 citations
https://doi.org/10.1200/jco.18.00605
The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma
2016 · Clinical Cancer Research · 84 citations
https://doi.org/10.1158/1078-0432.ccr-16-1576
Supplementary Material for: Real-world effectiveness of lipid-lowering medications on outcomes after stroke: potential implications of the new-user design
2022 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.20347443
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat